<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00550992</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000570260</org_study_id>
    <secondary_id>DCOG-INTERFANT-06</secondary_id>
    <secondary_id>EUDRACT-2005-004599-19</secondary_id>
    <secondary_id>CCLG-LK-2006-10</secondary_id>
    <nct_id>NCT00550992</nct_id>
  </id_info>
  <brief_title>Different Therapies in Treating Infants With Newly Diagnosed Acute Leukemia</brief_title>
  <acronym>Interfant06</acronym>
  <official_title>International Collaborative Treatment Protocol for Infants Under One Year With Acute Lymphoblastic or Biphenotypic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dutch Childhood Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>BFM Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CORS Monza Italy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Associazione Italiana Ematologia Oncologia Pediatrica</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Australian and New Zealand Children's Oncology Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>BFM Austria</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CLCG France Belgium Portugal</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>COALL Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CPH, Czech republic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>DFCI consortium USA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>FRALLE France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hong Kong</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>MD Anderson USA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>NOPHO Scandinavian countries</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>PINDA, Chile</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>PPLLSG Poland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Seattle USA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>SJCRH USA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>UKCCSG United Kingdom</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Dutch Childhood Oncology Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Giving chemotherapy before a donor stem cell transplant helps stop the growth of&#xD;
      cancer cells. It also helps stop the patient's immune system from rejecting the donor's stem&#xD;
      cells. When the healthy stem cells from a donor are infused into the patient they may help&#xD;
      the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets.&#xD;
      Sometimes the transplanted cells from a donor can make an immune response against the body's&#xD;
      normal cells. Giving cyclosporine, methotrexate, leucovorin, and antithymocyte globulin&#xD;
      before and after transplant may stop this from happening. It is not yet known which treatment&#xD;
      regimen is most effective in treating acute leukemia.&#xD;
&#xD;
      PURPOSE: This randomized clinical trial is studying how well different therapies work in&#xD;
      treating infants with newly diagnosed acute leukemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To compare an early intensification regimen comprising two &quot;acute myeloid leukemia&quot;&#xD;
           induction therapy blocks with a standard protocol IB regimen administered directly after&#xD;
           induction therapy in medium-risk (MR) and high-risk (HR) patients with newly diagnosed&#xD;
           acute lymphoblastic or biphenotypic leukemia.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To compare through a randomized study the role of these regimens in treating these&#xD;
           patients.&#xD;
&#xD;
        -  To compare the overall outcome of the Interfant-06 study with outcomes in the historical&#xD;
           control series, especially in the Interfant-99 study.&#xD;
&#xD;
        -  To compare the outcomes of low-risk, MR, or HR patients in this study with those of&#xD;
           patients in the historical control series Interfant-99 study.&#xD;
&#xD;
        -  To study which factors have independent prognostic value in patients treated with these&#xD;
           regimens.&#xD;
&#xD;
        -  To assess the role of stem cell transplantation in HR patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
        -  Induction therapy:&#xD;
&#xD;
             -  Prednisone phase: Patients receive prednisone orally or IV three times daily on&#xD;
                days 1-7 and methotrexate (MTX) and prednisolone (PRDL) intrathecally (IT) on day&#xD;
                1. Patients then proceed to remission induction therapy.&#xD;
&#xD;
             -  Remission induction phase: Patients receive dexamethasone (DEXA) IV or orally three&#xD;
                times daily on days 8-28 followed by a taper to 0 over 1 week; vincristine (VCR) IV&#xD;
                on days 8, 15, 22, and 29; cytarabine (ARA-C) IV over 30 minutes on days 8-21;&#xD;
                daunorubicin hydrochloride (DNR) IV over 1 hour on days 8 and 9; asparaginase (ASP)&#xD;
                IV over 1 hour or intramuscularly (IM) on days 15, 18, 22, 25, 29, and 33; MTX IT&#xD;
                on days 1 and 29*; and ARA-C IT on day 15. Patients also receive PRDL or&#xD;
                therapeutic hydrocortisone (HC) IT on days 1, 15, and 29.&#xD;
&#xD;
      NOTE: *Patients with CNS involvement at initial diagnosis also receive MTX IT on days 8 and&#xD;
      22. If CNS leukemia is still present at day 29, then patients receive weekly MTX IT until the&#xD;
      CNS is free of leukemia.&#xD;
&#xD;
      After completion of induction therapy, patients are stratified according to risk group&#xD;
      (low-risk [LR] vs medium-risk [MR] vs high-risk [HR]). Patients with low-risk disease are&#xD;
      assigned to treatment arm I. Patients with MR or HR disease that is in complete remission&#xD;
      (CR) on day 33 are randomized to 1 of 2 treatment arms. These patients are stratified&#xD;
      according to status (MR with rearranged MLL vs MR with unknown MLL vs HR).&#xD;
&#xD;
        -  Arm I (standard therapy):&#xD;
&#xD;
             -  Protocol IB therapy (beginning on day 36 of induction therapy): Patients receive&#xD;
                cyclophosphamide (CPM) IV over 1 hour on days 1 and 29 and oral mercaptopurine (MP)&#xD;
                on days 1-28; ARA-C IV on days 3-6, 10-13, 17-20, and 24-27; ARA-C IT on day 10;&#xD;
                and MTX IT on day 24. Patients also receive PRDL or therapeutic HC IT on days 10&#xD;
                and 24.&#xD;
&#xD;
             -  MARMA therapy:&#xD;
&#xD;
                  -  Part I: Patients receive oral MP once daily on days 1-14; high-dose (HD) MTX&#xD;
                     IV over 24 hours on days 1 and 8; leucovorin calcium orally or IV at 42, 48,&#xD;
                     and 54 hours after each dose of MTX until MTX plasma levels are safe; and MTX&#xD;
                     IT on days 2 and 9. Patients also receive PRDL or therapeutic HC IT on days 2&#xD;
                     and 9.&#xD;
&#xD;
                  -  Part II: Patients receive HD ARA-C IV over 3 hours twice daily with 12-hour&#xD;
                     intervals on days 15, 16, 22, and 23; and pegaspargase (PEG-ASP) IV over 1&#xD;
                     hour or IM on day 23.&#xD;
&#xD;
             -  OCTADA(D) reinduction therapy:&#xD;
&#xD;
                  -  Part I: At least 2 weeks after the completion of MARMA chemotherapy, patients&#xD;
                     receive oral dexamethasone (DEXA) three times daily on days 1-14, followed by&#xD;
                     a taper to 0 at day 21; oral thioguanine (TG) once daily on days 1-28; VCR IV&#xD;
                     on days 1, 8, 15, and 22; DNR IV over 1 hour on days 1, 8, 15, and 22; PEG-ASP&#xD;
                     IV over 1 hour or IM on day 1; ARA-C IV on days 2-5, 9-12, 16-19, and 23-26;&#xD;
                     and ARA-C IT on days 1 and 15. Patients also receive PRDL or therapeutic HC IT&#xD;
                     on days 1 and 15.&#xD;
&#xD;
                  -  Part II: Patients receive oral TG once daily on days 36-49; ARA-C IV once&#xD;
                     daily on days 37-40 and 45-48; and CPM IV over 1 hour on days 36 and 49.&#xD;
&#xD;
             -  Maintenance therapy: At least 2 weeks after completion of the last course of&#xD;
                OCTADA(D) chemotherapy, patients receive oral MP once daily; oral MTX once weekly;&#xD;
                MTX IT in weeks 1 and 15; and ARA-C IT in week 8. Patients also receive PRDL or&#xD;
                therapeutic HC IT in weeks 1, 8, and 15. Treatment continues for up to 104 weeks&#xD;
                after initial diagnosis in the absence of disease progression or unacceptable&#xD;
                toxicity.&#xD;
&#xD;
        -  Arm II (experimental therapy):&#xD;
&#xD;
             -  ADE therapy (beginning on day 36 of induction therapy: Patients receive ARA-C IV&#xD;
                every 12 hours on days 1-10; DNR IV over 1 hour on days 1, 3, and 5; etoposide&#xD;
                (VP-16) IV over 4 hours on days 1-5; and ARA-C IT on day 1. Patients also receive&#xD;
                PRDL or therapeutic HC IT on day 1.&#xD;
&#xD;
             -  MAE therapy: Patients receive ARA-C IV every 12 hours on days 1-10; mitoxantrone&#xD;
                hydrochloride IV over 1 hour on days 1, 3, and 5; VP-16 IV over 4 hours on days&#xD;
                1-5; and MTX IT on day 1. Patients also receive PRDL or therapeutic HC IT on day 1.&#xD;
&#xD;
             -  MARMA therapy:&#xD;
&#xD;
                  -  Part I: Patients receive oral MP once daily on days 1-14; high-dose (HD) MTX&#xD;
                     IV over 24 hours on days 1 and 8; leucovorin calcium orally or IV at 42, 48,&#xD;
                     and 54 hours after each dose of MTX until MTX plasma levels are safe; and MTX&#xD;
                     IT on days 2 and 9. Patients also receive PRDL or therapeutic HC IT on days 2&#xD;
                     and 9.&#xD;
&#xD;
                  -  Part II: Patients receive HD ARA-C IV over 3 hours twice daily with 12-hour&#xD;
                     intervals on days 15, 16, 22, and 23; and pegaspargase (PEG-ASP) IV over 1&#xD;
                     hour or IM on day 23.&#xD;
&#xD;
             -  OCTADA reinduction therapy:&#xD;
&#xD;
                  -  Part I: At least 2 weeks after the completion of MARMA chemotherapy, patients&#xD;
                     receive oral DEXA three times daily on days 1-14, followed by a taper to 0 at&#xD;
                     day 21; oral TG once daily on days 1-28; VCR IV on days 1, 8, 15, and 22;&#xD;
                     PEG-ASP IV over 1 hour or IM on day 1; ARA-C IV on days 2-5, 9-12, 16-19, and&#xD;
                     23-26; and ARA-C IT on days 1 and 15. Patients also receive PRDL or&#xD;
                     therapeutic HC IT on days 1 and 15.&#xD;
&#xD;
                  -  Part II: Beginning 1 week after completion of part I, patients receive oral TG&#xD;
                     once daily on days 36-49; ARA-C IV once daily on days 37-40 and 45-48; and CPM&#xD;
                     IV over 1 hour on days 36 and 49.&#xD;
&#xD;
             -  Maintenance therapy: At least 2 weeks after completion of the last course of OCTADA&#xD;
                chemotherapy, patients receive oral MP once daily; oral MTX once weekly; MTX IT in&#xD;
                weeks 1 and 15; and ARA-C IT in week 8. Patients also receive PRDL or therapeutic&#xD;
                HC IT in weeks 1, 8, and 15. Treatment continues for up to 104 weeks after initial&#xD;
                diagnosis in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      All HR patients with a suitably matched donor are scheduled for allogeneic stem cell&#xD;
      transplantation (SCT) after MARMA or before or during OCTADA(D) chemotherapy, provided they&#xD;
      are in CR1 and no more than 8 months have elapsed since initial diagnosis.&#xD;
&#xD;
        -  Conditioning regimens for allogeneic SCT:&#xD;
&#xD;
             -  Matched sibling donor (MSD): Patients receive oral busulfan (BU) every 6 hours on&#xD;
                days -7 to -4; CPM IV over 1 hour on days -3 to -2; and melphalan (MEL) IV over 1&#xD;
                hour on day -1.&#xD;
&#xD;
             -  Matched donors (MD): Patients receive oral BU every 6 hours on days -7 to -4; CPM&#xD;
                IV over 1 hour on days -3 to -2; MEL IV over 1 hour on day -1; and anti-thymocyte&#xD;
                globulin (ATG) IV over 4 hours on days -3 to -1.&#xD;
&#xD;
        -  Graft-Versus-Host Disease (GVHD) prophylaxis and therapy:&#xD;
&#xD;
             -  MSD: Patients receive cyclosporine (CsA) IV or orally twice daily beginning on day&#xD;
                -1 and continuing to day 60 after SCT, followed by a taper in the absence of GVHD&#xD;
                symptoms.&#xD;
&#xD;
             -  MD: Patients receive CsA as in group MSD; MTX IV on days 1, 3, and 6; leucovorin&#xD;
                calcium IV on days 2, 4, and 7; and ATG IV on days -3 to -1.&#xD;
&#xD;
        -  Allogeneic SCT: Patients undergo infusion of bone marrow, peripheral blood, or cord&#xD;
           blood hematopoietic stem cells on day 0.&#xD;
&#xD;
      After completion of study therapy, patients are followed periodically for up to 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">January 2006</start_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free survival</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free survival within each risk group (i.e., low-risk, medium-risk, or high-risk)</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">445</enrollment>
  <condition>Leukemia</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>anti-thymocyte globulin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>asparaginase</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>busulfan</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclosporine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cytarabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>daunorubicin hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leucovorin calcium</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melphalan</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mercaptopurine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mitoxantrone hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pegaspargase</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisolone</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisone</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>therapeutic hydrocortisone</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>thioguanine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vincristine sulfate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>allogeneic bone marrow transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>allogeneic hematopoietic stem cell transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>umbilical cord blood transplantation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
          -  Diagnosis of acute lymphoblastic leukemia (ALL) or biphenotypic leukemia meeting the&#xD;
             following criteria:&#xD;
&#xD;
               -  Based on European Group for the Classification of Acute Leukemia (EGIL)&#xD;
                  diagnostic criteria&#xD;
&#xD;
               -  Newly diagnosed disease&#xD;
&#xD;
               -  Verified by morphology and confirmed by cytochemistry and immunophenotyping&#xD;
&#xD;
                    -  Trephine biopsy is recommended (unless diagnosis can be confirmed by&#xD;
                       peripheral blood examination) in the event that bone marrow aspiration&#xD;
                       results in a &quot;dry tap&quot;&#xD;
&#xD;
          -  Must have MLL gene rearrangements documented by split-signal fluorescence in situ&#xD;
             hybridization and meets 1 of the following risk criteria:&#xD;
&#xD;
               -  Low-risk disease, defined as all MLL germline cases&#xD;
&#xD;
               -  Medium-risk disease, defined by 1 of the following criteria:&#xD;
&#xD;
                    -  MLL status unknown&#xD;
&#xD;
                    -  MLL rearranged AND age &gt; 6 months&#xD;
&#xD;
                    -  MLL rearranged AND age &lt; 6 months AND WBC &lt; 300 x 10^9/L AND prednisone good&#xD;
                       response&#xD;
&#xD;
               -  High-risk disease, defined by MLL rearrangement AND meets the following criteria:&#xD;
&#xD;
                    -  Age at diagnosis &lt; 6 months (i.e., &lt; 183 days)&#xD;
&#xD;
                    -  WBC ≥ 300 x 10^9/L AND/OR prednisone poor response&#xD;
&#xD;
          -  Minimum donor and stem cell requirements for high-risk patients undergoing stem cell&#xD;
             transplantation:&#xD;
&#xD;
               -  Donor meeting 1 of the following criteria:&#xD;
&#xD;
                    -  HLA-identical sibling&#xD;
&#xD;
                    -  Very well-matched related or unrelated donor&#xD;
&#xD;
                    -  Must be HLA compatible in 10/10 or 9/10 alleles by 4 digit/allele&#xD;
                       high-resolution molecular genotyping&#xD;
&#xD;
               -  Stem cell source&#xD;
&#xD;
                    -  Bone marrow (preferred source) OR peripheral blood stem cells of filgrastim&#xD;
                       [G-CSF]-stimulated donors OR cord blood&#xD;
&#xD;
                         -  Highly-matched unrelated umbilical cord blood (UCB) (&gt; 7/8 matches&#xD;
                            identified by high-resolution typing) accepted if a sibling donor is&#xD;
                            not able to donate bone marrow AND UCB with a sufficient number of&#xD;
                            nucleated cells (NCs) (i.e., &gt; 1.5 x 10^7/kg recipient body weight&#xD;
                            [BW]) is cryopreserved&#xD;
&#xD;
               -  Must have ≥ 3 x 10^8 NCs/kg BW OR 3 x 10^6/kg BW CD34-positive cells available&#xD;
                  for transplantation&#xD;
&#xD;
          -  CNS or testicular leukemia at diagnosis allowed&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Mature B-ALL, defined by the immunophenotypical presence of surface immunoglobulins or&#xD;
             t(8;14) and breakpoint as in B-ALL&#xD;
&#xD;
          -  Presence of the t(9;22) (q34;q11) or bcr-abl fusion in the leukemic cells (if data are&#xD;
             not known, patient still may be eligible)&#xD;
&#xD;
          -  Relapsed ALL&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  More than 4 weeks since prior systemic corticosteroids&#xD;
&#xD;
               -  Corticosteroids by aerosol are allowed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>1 Year</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rob Pieters, MD, MSC, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Prinses Maxima Centrum voor kinderoncologie Utrecht</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Martin Schrappe, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital Schleswig-Holstein</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lewis B. Silverman, MD</last_name>
      <phone>617-632-5285</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Jude Children's Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - St. Jude Children's Research Hospital</last_name>
      <phone>901-595-4644</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>M. D. Anderson Cancer Center at University of Texas</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - M. D. Anderson Cancer Center at the U</last_name>
      <phone>713-792-3245</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital and Regional Medical Center - Seattle</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Blythe Thomson, MD</last_name>
      <phone>206-987-2106</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Anna Children's Hospital</name>
      <address>
        <city>Vienna</city>
        <zip>A-1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Georg Mann, MD</last_name>
      <phone>43-1-4017-1250</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Universitaire Des Enfants Reine Fabiola</name>
      <address>
        <city>Brussels</city>
        <zip>1020</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alice Ferster, MD</last_name>
      <phone>32-2-477-2678</phone>
      <email>aferster@ulb.ac.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Motol</name>
      <address>
        <city>Prague</city>
        <zip>150 06</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Stary, MD</last_name>
      <phone>420-2-2443-6401</phone>
      <email>jan.stary@lfmotol.cuni.cz</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHR Hotel Dieu</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francoise Mechinaud, MD</last_name>
      <phone>33-1-4249-9046</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Medical Center Hamburg - Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>D-20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gritta Janka-Schaub</last_name>
      <phone>49-404-2803-2580</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>D-30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Schrappe, MD, PhD</last_name>
      <phone>49-511-532-6713</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nuovo Ospedale San Gerardo at University of Milano-Bicocca</name>
      <address>
        <city>Monza</city>
        <zip>20052</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Biondi, MD</last_name>
      <phone>39-039-233-3661</phone>
      <email>biondi@galactica.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Erasmus MC - Sophia Children's Hospital</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 GJ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rob Pieters, MD, MSC, PhD</last_name>
      <phone>31-88-97 26003</phone>
      <email>rpieters@prinsesmaximacentrum.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Great Ormond Street Hospital for Children</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>WC1N 3JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Phil Ancliff, MD</last_name>
      <phone>44-20-7829-8831</phone>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>October 22, 2007</study_first_submitted>
  <study_first_submitted_qc>October 25, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 30, 2007</study_first_posted>
  <last_update_submitted>July 29, 2019</last_update_submitted>
  <last_update_submitted_qc>July 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>untreated childhood acute lymphoblastic leukemia</keyword>
  <keyword>T-cell childhood acute lymphoblastic leukemia</keyword>
  <keyword>acute undifferentiated leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Hydrocortisone</mesh_term>
    <mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
    <mesh_term>Hydrocortisone acetate</mesh_term>
    <mesh_term>Hydrocortisone hemisuccinate</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Daunorubicin</mesh_term>
    <mesh_term>Asparaginase</mesh_term>
    <mesh_term>Mercaptopurine</mesh_term>
    <mesh_term>Mitoxantrone</mesh_term>
    <mesh_term>Thioguanine</mesh_term>
    <mesh_term>Pegaspargase</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

